prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.
Company profile
Ticker
PROK, PROK-BIVA, PROK-MM
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Social Capital Suvretta Holdings Corp. III
SEC CIK
Corporate docs
Subsidiaries
ProKidney Corp. GP Limited • ProKidney LP • ProKidney, LLC • ProKidney Acquisition Company, LLC ...
IRS number
981586514
PROK stock data
Latest filings (excl ownership)
8-K
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
25 Mar 24
S-8
Registration of securities for employees
22 Mar 24
8-K
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K/A
Departure of Directors or Certain Officers
18 Mar 24
8-K/A
Departure of Directors or Certain Officers
18 Mar 24
8-K
Departure of Directors or Certain Officers
12 Feb 24
8-K
Regulation FD Disclosure
26 Jan 24
8-K
Entry into a Material Definitive Agreement
19 Jan 24
424B5
Prospectus supplement for primary offering
19 Jan 24
Transcripts
Latest ownership filings
4
Darin J. Weber
17 Apr 24
4
Darin J. Weber
16 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
144
Notice of proposed sale of securities
12 Apr 24
4
Ulrich Peter Alfred Ernst
2 Apr 24
3
Ulrich Peter Alfred Ernst
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
James Coulston
5 Mar 24
4
Todd C Girolamo
5 Mar 24
4
Darin J. Weber
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 191.39 mm | 191.39 mm | 191.39 mm | 191.39 mm | 191.39 mm | 191.39 mm |
Cash burn (monthly) | 17.39 mm | 26.24 mm | 15.54 mm | 13.13 mm | 7.93 mm | 6.70 mm |
Cash used (since last report) | 115.33 mm | 174.07 mm | 103.06 mm | 87.08 mm | 52.57 mm | 44.46 mm |
Cash remaining | 76.06 mm | 17.32 mm | 88.33 mm | 104.31 mm | 138.82 mm | 146.93 mm |
Runway (months of cash) | 4.4 | 0.7 | 5.7 | 7.9 | 17.5 | 21.9 |
Institutional ownership, Q3 2023
90.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 71 |
Opened positions | 17 |
Closed positions | 6 |
Increased positions | 15 |
Reduced positions | 27 |
13F shares | Current |
---|---|
Total value | 186.46 bn |
Total shares | 209.88 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tolerantia | 94.68 mm | $817.07 mm |
Carso, S.A. de C.V. Inversora | 63.12 mm | $544.71 mm |
Palihapitiya Chamath | 11.57 mm | $56.13 mm |
Social Capital | 11.57 mm | $53.00 bn |
MS Morgan Stanley | 10.29 mm | $47.11 bn |
Suvretta Capital Management | 3.87 mm | $17.71 bn |
Vanguard | 3.29 mm | $15.08 bn |
BLK Blackrock | 2.81 mm | $12.88 bn |
Bleichroeder | 2.00 mm | $9.16 bn |
BAC Bank Of America | 1.42 mm | $6.51 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Apr 24 | Darin J. Weber | Class A Ordinary Shares | Sell | Dispose S | No | Yes | 2.5 | 17,238 | 43.10 k | 172,432 |
12 Apr 24 | Darin J. Weber | Class A Ordinary Shares | Sell | Dispose S | No | Yes | 1.73 | 84,103 | 145.50 k | 189,670 |
1 Apr 24 | Ulrich Peter Alfred Ernst | Employee stock option Class A Ordinary Shares | Grant | Acquire A | No | No | 1.6 | 335,000 | 536.00 k | 335,000 |
1 Apr 24 | Darin J. Weber | Class A Ordinary Shares | Sell | Dispose S | No | Yes | 1.69 | 300 | 507.00 | 273,773 |
1 Mar 24 | James Coulston | Employee stock option Class A Ordinary Shares | Grant | Acquire A | No | No | 1.61 | 275,000 | 442.75 k | 275,000 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
17 Apr 24
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
15 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
15 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
8 Mar 24
Morgan Stanley Assumes ProKidney at Equal-Weight, Announces Price Target of $3
7 Mar 24